PCRX Pacira BioSciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1396814 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.7%
TTM net income YoY76.0%
TTM EPS YoY97.9%
Revenue 3-yr CAGR3.7%
Net income 3-yr CAGR75.5%
Margins
Gross margin78.7%
Operating margin4.8%
Net margin5.1%
FCF margin22.7%
EBITDA margin12.4%
Returns
ROE5.2%
ROA3.0%
ROIC (approx.)4.2%
Asset turnover0.59x
Leverage & solvency
Liabilities / assets40.8%
Debt / equity0.41x
Current ratio4.68x
Interest coverage2.54x
Cash quality & payout
Operating cash flow / net income4.69x
Accruals ratio-11.1%
Payout ratio—
Capex / revenue1.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $726.41M | $700.97M | $674.98M | $666.82M | $541.53M |
| Cost of revenue | $149.75M | $170.43M | $184.67M | $199.29M | $140.25M |
| Gross profit | $576.66M | $530.54M | $490.31M | $467.53M | $401.28M |
| R&D expense | $117.31M | $81.58M | $76.26M | $84.80M | $55.55M |
| SG&A expense | $368.76M | $294.10M | $269.44M | $254.52M | $199.34M |
| Operating income | $19.19M | -$73.37M | $87.67M | $60.02M | $89.92M |
| Interest expense | $17.45M | $16.57M | $20.31M | $39.98M | $31.75M |
| Pretax income | $16.87M | -$63.11M | $61.70M | $13.30M | $56.40M |
| Income tax | $9.84M | $36.45M | $19.75M | -$2.61M | $14.42M |
| Net income | $7.03M | -$99.56M | $41.95M | $15.91M | $41.98M |
| EBITDA | $110.21M | $5.41M | $163.25M | $151.53M | $118.47M |
| EPS (basic) | 0.16 | -2.15 | 0.91 | 0.35 | 0.95 |
| EPS (diluted) | 0.16 | -2.15 | 0.89 | 0.34 | 0.92 |
| Weighted avg. shares (diluted) | 45.04M | 46.24M | 51.98M | 46.54M | 45.63M |
| Balance sheet | |||||
| Cash & equivalents | $158.54M | $276.77M | $153.30M | $104.14M | $585.58M |
| Short-term investments | $79.88M | $207.84M | $125.28M | $184.51M | $70.83M |
| Receivables | $124.07M | $113.30M | $105.56M | $98.40M | $96.32M |
| Inventory | $152.86M | $125.28M | $104.35M | $96.06M | $98.55M |
| Current assets | $547.97M | $745.13M | $509.99M | $498.33M | $866.05M |
| PP&E, net | $140.69M | $167.17M | $173.93M | $183.51M | $188.40M |
| Goodwill | $20.21M | $0 | $163.24M | $163.24M | $145.20M |
| Intangibles | $368.10M | $425.97M | $483.26M | $540.55M | $623.97M |
| Total assets | $1.26B | $1.55B | $1.57B | $1.68B | $2.08B |
| Current liabilities | $120.59M | $309.92M | $97.38M | $147.77M | $521.12M |
| Short-term debt | $0 | $201.78M | — | — | — |
| Long-term debt | $372.19M | $383.55M | $522.44M | $689.47M | — |
| Total debt | $372.19M | $585.32M | $522.44M | $689.47M | — |
| Total liabilities | $571.81M | $775.17M | $704.26M | $906.19M | $1.34B |
| Shareholders' equity | $693.11M | $778.35M | $870.13M | $775.01M | $730.41M |
| Net debt | $213.64M | $308.55M | $369.14M | $585.33M | — |
| Shares outstanding | 41.12M | 46.24M | 46.48M | 45.93M | 44.73M |
| Cash flow statement | |||||
| Operating cash flow | $151.99M | $189.39M | $154.65M | $145.27M | $125.72M |
| Capital expenditure | $15.33M | $10.64M | $15.16M | $30.08M | $45.87M |
| Free cash flow | $136.66M | $178.75M | $139.49M | $115.20M | $79.85M |
| Investing cash flow | $99.48M | -$83.28M | $77.54M | -$225.19M | -$20.79M |
| Financing cash flow | -$369.63M | $17.36M | -$183.03M | -$401.53M | $380.69M |
| Depreciation & amortization | $91.02M | $78.78M | $75.57M | $91.50M | $28.55M |
| Stock-based compensation | $57.50M | $51.17M | $47.90M | $48.09M | $42.25M |
| Share buybacks | $148.33M | $25.00M | $0 | $0 | — |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.